We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

News · January 31, 2020

ASCO GI 2020: Maintenance Capecitabine or Durvalumab Following First-Line Chemotherapy May Improve Outcomes in Advanced Gastroesophageal Adenocarcinoma

The comparative trial will continue to accrue patients.

PracticeUpdate Editorial Team

 

Further Reading